NFCR Applauds AstraZeneca’s $50 Billion Investment to Advance Cancer Research and Innovation in U.S.
National Foundation for Cancer Research (NFCR) shared a post on LinkedIn by AstraZeneca, adding:
“A major step forward for cancer research and innovation in the U.S..
We applaud AstraZeneca’s landmark $50 billion investment in medicines manufacturing and R and D – including a new facility in Virginia focused on chronic diseases. Strategic investments like this accelerate scientific discovery, bolster our shared ecosystem, and bring us closer to saving more lives.
At NFCR, we know that bold commitments to research are what make real breakthroughs possible”
Quoting AstraZeneca‘
“Today we announced plans to invest $50 billion in medicines manufacturing and R and D in the United States by 2030. This landmark investment supports our ambition to achieve $80 billion in total revenue by that year, with 50% expected to be generated in the US.
Our plans include a new, state-of-the-art drug substance manufacturing facility focused on chronic diseases in the Commonwealth of Virginia – the largest single manufacturing investment we’ve ever made – underpinning our belief in America’s innovation in biopharmaceuticals and our commitment to deliver our innovative medicines to millions more patients.
You can watch the video here”
More posts featuring NFCR and AstraZeneca on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023